Atlas Trials

Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer

Clinical trial NCT06653972 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06653972
Sponsor
Wang Jiayu
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Her2-negative Metastatic Breast CancerVinorelbineLiposomal Doxorubicin
Start date
2024-11-01
Primary completion
2026-02-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.